Arrowhead Pharmaceuticals, Inc. (ARWR) Reaches $9.12 52-Week High; 7 Analysts Are Bullish Castlight Health, Inc. (CSLT) Last Week

May 9, 2018 - By Marguerite Chambers

Castlight Health, Inc. (NYSE:CSLT) Logo

Among 13 analysts covering Castlight Health (NYSE:CSLT), 7 have Buy rating, 1 Sell and 5 Hold. Therefore 54% are positive. Castlight Health had 33 analyst reports since October 9, 2015 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Monday, September 4 with “Hold”. As per Friday, October 6, the company rating was maintained by Canaccord Genuity. FBR Capital initiated Castlight Health, Inc. (NYSE:CSLT) rating on Wednesday, November 18. FBR Capital has “Mkt Perform” rating and $5 target. As per Friday, June 30, the company rating was maintained by Canaccord Genuity. On Wednesday, February 21 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating given on Wednesday, April 25 by Cantor Fitzgerald. The stock has “Underweight” rating by Morgan Stanley on Friday, May 12. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, November 5. Cantor Fitzgerald maintained the shares of CSLT in report on Monday, November 6 with “Hold” rating. Canaccord Genuity maintained it with “Hold” rating and $500 target in Thursday, August 3 report. See Castlight Health, Inc. (NYSE:CSLT) latest ratings:

25/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $5.0000 Maintain
21/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $5.0 Maintain
30/01/2018 Broker: Morgan Stanley Rating: Sell
31/01/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Upgrade

The stock of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) hit a new 52-week high and has $9.39 target or 3.00% above today’s $9.12 share price. The 6 months bullish chart indicates low risk for the $791.50M company. The 1-year high was reported on May, 9 by Barchart.com. If the $9.39 price target is reached, the company will be worth $23.75M more. The stock increased 17.68% or $1.37 during the last trading session, reaching $9.12. About 3.38M shares traded or 145.10% up from the average. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has risen 265.61% since May 9, 2017 and is uptrending. It has outperformed by 254.06% the S&P500.

More notable recent Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news were published by: Schaeffersresearch.com which released: “2 Upgraded Drug Stocks Squeezing Shorts” on May 09, 2018, also Globenewswire.com with their article: “Recent Analysis Shows Extreme Networks, Lumber Liquidators, Owens-Illinois, Arrowhead Pharmaceuticals, Intrepid …” published on May 09, 2018, Benzinga.com published: “22 Stocks Moving In Wednesday’s Pre-Market Session” on May 09, 2018. More interesting news about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on May 09, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with publication date: May 08, 2018.

Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. The company has market cap of $791.50 million. The Company’s pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. It currently has negative earnings. The firm also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma.

Among 8 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arrowhead Research Corp has $20.0 highest and $2.0 lowest target. $5.92’s average target is -35.09% below currents $9.12 stock price. Arrowhead Research Corp had 28 analyst reports since August 5, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Neutral” rating and $5 target in Monday, February 12 report. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, September 25 report. Jefferies maintained the shares of ARWR in report on Monday, June 26 with “Hold” rating. The firm earned “Hold” rating on Monday, February 12 by FBR Capital. The firm has “Overweight” rating given on Monday, November 27 by PiperJaffray. The rating was upgraded by Piper Jaffray to “Buy” on Monday, November 27. Cantor Fitzgerald initiated it with “Buy” rating and $15 target in Friday, August 19 report. The rating was maintained by FBR Capital with “Hold” on Tuesday, March 27. The firm has “Neutral” rating given on Wednesday, November 30 by Piper Jaffray. Piper Jaffray maintained the shares of ARWR in report on Thursday, September 14 with “Hold” rating.

Investors sentiment decreased to 1.23 in 2017 Q4. Its down 0.82, from 2.05 in 2017Q3. It is negative, as 10 investors sold Castlight Health, Inc. shares while 21 reduced holdings. 16 funds opened positions while 22 raised stakes. 46.25 million shares or 3.11% more from 44.86 million shares in 2017Q3 were reported. Raymond James And Assoc stated it has 53,900 shares or 0% of all its holdings. Ameritas Inv stated it has 0% of its portfolio in Castlight Health, Inc. (NYSE:CSLT). California Pub Employees Retirement Sys has invested 0% in Castlight Health, Inc. (NYSE:CSLT). Legal And General Grp Public Limited Co reported 10,387 shares stake. 22,417 were reported by Teacher Retirement Systems Of Texas. Voya Investment Management owns 26,929 shares. 1.14 million are owned by State Street. Gmt Capital reported 0.05% in Castlight Health, Inc. (NYSE:CSLT). 15,122 were reported by Virtu Fin Limited Liability Com. Principal Grp Incorporated reported 12,127 shares. Schwab Charles Invest Mngmt owns 262,271 shares. Ubs Asset Management Americas Incorporated owns 0% invested in Castlight Health, Inc. (NYSE:CSLT) for 46,500 shares. Atlantic Trust Gru Lc has 0% invested in Castlight Health, Inc. (NYSE:CSLT) for 1,204 shares. 96,004 are owned by Citadel Advsrs Ltd Llc. Parallax Volatility Advisers Lp invested in 0% or 9,660 shares.

It closed at $3.85 lastly. It is down 6.15% since May 9, 2017 and is uptrending. It has underperformed by 5.40% the S&P500.

Since February 15, 2018, it had 0 buys, and 4 selling transactions for $120,817 activity. Nolan Mangini Siobhan had sold 1,011 shares worth $3,741. 10,644 shares were sold by DOYLE JOHN C, worth $38,624 on Tuesday, February 20.

Castlight Health, Inc. operates a health benefits platform in the United States. The company has market cap of $522.05 million. The companyÂ’s platform engages employees to make better health decisions and enables employers to communicate and measure their benefit programs. It currently has negative earnings. The Company’s platform also provides real-time insight into employee engagement with benefits and programs enabling employers to monitor and adjust their strategies.

Castlight Health, Inc. (NYSE:CSLT) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>